English: Giant Platelets on a blood smear (40x). Español: Plaquetas en un frotis sanguíneo (40x). (Photo credit: Wikipedia)
Researchers cautioned that study results involving laboratory mouse models do not always translate into clinical treatment of human patients
Researchers used blood platelets and bone marrow cells to deliver potentially curative
to mouse models of the human genetic disorder Hurler syndrome – an often fatal condition that causes organ damage and other medical complications.
Scientists from Cincinnati Children’s Hospital Medical Center and the National Institute of Neurological Disorders and Stroke (NINDS) report their unique strategy for treating the disease the week of Feb. 3-7 in Proceedings of the National Academy of Sciences (PNAS).
Researchers were able to genetically insert into the cells a gene that produces a critical lysosomal enzyme (called IDUA) and then inject the engineered cells into mice to treat the disorder. Follow up tests showed the treatment resulted in a complete metabolic correction of the disease, according to the authors.
“Our findings demonstrate a unique and somewhat surprising delivery pathway for lysosomal enzymes,” said Dao Pan, PhD, corresponding author and researcher in the Division of Experimental Hematology and Cancer Biology at Cincinnati Children’s. “We show proof of concept that platelets and megakaryocytes are capable of generating and storing fully functional lysosomal enzymes, which can lead to their targeted and efficient delivery to vital tissues where they are needed.”
The mice tested in the study modeled human Hurler syndrome, a subset of disease known as mucopolysaccharidosis type I (MPS I), one of the most common types of lysosomal storage diseases. MPS I is a lysosomal storage disease in which people do not make an enzyme called lysosomal alpha-L-iduronidase (IDUA).
IDUA helps break down sugar molecules found throughout the body, often in mucus and fluids around joints, according to the National Library of Medicine/National Institutes of Health. Without IDUA, sugar molecules build up and cause organ damage. Depending on severity, the syndrome can also cause deafness, abnormal bone growth, heart valve problems, joint disease, intellectual disabilities and death.
Enzyme replacement therapy can be used to treat the disease, but it is only temporary and not curative. Bone marrow transplant using hematopoietic stem cells also has been tested on some patients with mixed results. The transplant procedure can carry severe risks and does not always work.
Pan and her colleagues – including Roscoe O. Brady, MD, a researcher at NINDS – report that using platelets and megakaryocytes for gene therapy is effective and could reduce the risk of activating cancer-causing oncogenes in hematopoietic stem cells.
The authors said tests showed that human megakaryocytic cells were capable of overexpressing IDUA, revealing their capacity for potential therapeutic benefit. While engineering megakaryocytes and platelets for infusion into their mouse models of Hurler, the scientists report they were able to release IDUA directly into amply sized extracellular spaces or inside micro-particles as the cells matured or activated. The cells were able to produce and package large amounts of functional IDUA and retained the capacity to cross-correct patient cells.
After infusing mouse models of Hurler with the genetically modified cells, researchers said this led to long-term normalization of IDUA levels in the animal’s blood with versatile delivery routes and on-target preferential distribution to the liver and spleen. The treatment led to a complete metabolic correction of MPS I in most peripheral organs of the mice.
Researchers cautioned that study results involving laboratory mouse models do not always translate into clinical treatment of human patients, and that additional research is needed for this prospective therapy.
The Latest on: Hurler syndrome
via Google News
The Latest on: Hurler syndrome
- Little boy's legacy is saving other Hoosier childrenon July 26, 2022 at 1:36 pm
Eric Holcomb signed the bill, and it went into effect in July of that year. It adds newborn testing for Krabbe disease, Pompe disease and Hurler's syndrome in Indiana. The cost is $10.70 per infant, ...
- Enzyme Replacement Therapy Market Worth $15.18...on July 22, 2022 at 4:45 am
The therapy is generally applied in rare and lysosomal storage diseases, including Pompe disease, Tay-Sachs disease, Fabry disease, Gaucher disease, and Hurler syndrome. Researchers and players ...
- Bone marrow transplantationon July 18, 2022 at 6:17 pm
Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Total body irradiation and ...
- Hurler Syndrome Treatment Market – Globally Market Size, Analysis, Share, Research, Business Growth and Forecast to 2029on July 14, 2022 at 6:36 am
The hurler syndrome treatment market is expected to witness market growth at a rate of 9.90% in the forecast period of 2022 to 2029. Data Bridge Market Research report on the hurler syndrome ...
- Hurler Syndrome Treatment Market – Globally Market Size, Analysis, Share, Research, Business Growth and Forecast to 2029on July 8, 2022 at 5:03 am
Jul 08, 2022 (Heraldkeepers) -- The hurler syndrome treatment market is expected to witness market growth at a rate of 9.90% in the forecast period of 2022 to 2029. Data Bridge Market Research ...
- Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndromeon December 5, 2021 at 8:14 pm
Allogeneic hematopoietic stem-cell transplantation is the standard of care for Hurler syndrome (mucopolysaccharidosis type I, Hurler variant [MPSIH]). However, this treatment is only partially ...
- Girl, 4, donates bone marrow to little brother with rare genetic disorderon December 9, 2020 at 6:23 am
When Eli Vasquez was diagnosed with Hurler syndrome as a baby, his older sister Olivia held the key to saving his life.Dec. 9, 2020 ...
- Hunter syndromeon November 15, 2020 at 3:00 pm
Hunter syndrome was able to induce expression of the IDS enzyme that is deficient in the disease. ... was able to induce expression of the IDUA enzyme missing in the disease, which is also known as ...
- Chinese Scientists Say They’ve Found a Safer Alternative to CRISPRon August 19, 2020 at 8:03 am
Researchers from China's Peking University have developed a new gene-editing technology — and they think it shows promise as a CRISPR alternative for fighting human diseases. But while CRISPR ...
- JCRファーマ株式会社on August 11, 2020 at 4:51 pm
JCR Pharmaceuticals to initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo Oct 26 (Reuters) - JCR Pharmaceuticals Co Ltd :Says it will initiate ...
via Bing News